ERBB2 and breast cancer: To date, trastuzumab is still the only anti-HER2 mAb therapy available for gastric cancer [24], partly because several treatment strategies developed in the past that showed promise in the treatment of breast cancers failed to show clinical benefits in treating gastric cancer [25].